Nima Partners with Global Allergy Leader ALK for European Distribution
Today, Nima, the pioneer in connected food sensors, announces their partnership with global allergy leader, ALK, for European distribution of its portable gluten sensor. ALK handpicked Nima based on the science and validation behind its sensors and the rigor to which it tests and builds its products.
ALK is a research-driven, global pharmaceutical company focusing on allergy prevention, diagnosis and treatment for close to 100 years. They are the foremost innovators in allergy immunotherapy, a unique treatment which reduces allergic symptoms and treats the cause of the allergy. Since its inception, ALK has been working to improve quality of life for allergy patients.
The Nima Gluten Sensor is now available from ALK’s new direct-to-consumer site, klarify.me. This partnership is the major first step in Nima’s international channel expansion. The Gluten Sensor is now available in Germany and will be available in the United Kingdom next month.
For the millions of people around the world with food allergies, eating foods they haven’t prepared themselves can be incredibly dangerous and nerve wracking. Nima hopes to relieve some of the anxiety that comes with eating out. The Nima Gluten Sensor is a quick and portable device that tests for the presence of the gluten proteins that cause allergic reactions. Early this month, Nima also launched its Peanut Sensor in the U.S.
“Nima is the leader in portable allergy testing,” said Mads Lacoppidan, Head of Consumer Care Division at ALK. “We are incredibly impressed with the Nima Gluten Sensor and are proud to add it to our curated portfolio of allergy related products on klarify.me. Nima has put their sensors through rigorous testing and have achieved astounding results representing its accuracy and reliability clearly evidenced by scientific data which is now published in peer-reviewed journals.”
“More than 15 million people in the United States are battling food allergies and there are even more worldwide,” said Shireen Yates, CEO and co-founder of Nima. “We are so eager to get this device into the hands of more people around the world to help them make more informed decisions about what they eat.”
Founded in 2013, Nima is a science-driven technology company making the world safer for people who want and need to know what’s in their food. Through people-friendly products that identify individual ingredients in food, and a growing community of users and data, every day Nima enables people to enjoy what’s on their plates. Co-founders Shireen Yates and Scott Sundvor created Nima out of personal experience with food intolerances. To date, Nima has raised more than $15 million, including financing from Foundry Group, Upfront Ventures, SoftTech VC, SK Ventures and Lemnos Labs, with additional federal grants from the National Institutes of Health. For more Nima news, visit our blog or press section.
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,300 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.
Max Borges Agency
Christian Cooper, 305-374-4404 x164
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Grand Prize Winner in $1.75M Water Abundance XPRIZE Announced at XPRIZE Visioneering 201822.10.2018 17:49 | Pressemelding
During Visioneering 2018, XPRIZE’s annual gathering of philanthropists and innovators to evaluate concepts for future competitions, the Foundation revealed the results of its latest, completed XPRIZE. The Skysource / Skywater Alliance was announced as the grand prize winner of the $1.75M Water Abundance XPRIZE, a two-year competition aimed at alleviating the global water crisis with energy-efficient technologies that harvest fresh water from thin air. In addition at Visioneering, five new prize concepts were evaluated with top honors going to a prize concept called “Coral Survival”, a prize designed to protect and restore coral reefs. This prize will move forward into the XPRIZE pipeline. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181022005795/en/ The Skysource / Skywater Alliance team, based in Venice Beach, California, wins the Water Abundance XPRIZE (Photo: Business Wire) The Water Abundance XPRIZE, powered by the Tat
Positive Trial Results with Filgotinib in Psoriatic Arthritis and Ankylosing Spondylitis Both Published in The Lancet22.10.2018 17:15 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that detailed results from two clinical trials evaluating filgotinib, an investigational, selective JAK1 inhibitor, for the treatment of psoriatic arthritis and ankylosing spondylitis were both published in The Lancet. The publication of the Phase 2 EQUATOR data also coincides with a plenary session presentation at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting. “The results of the EQUATOR and TORTUGA studies demonstrate that filgotinib improved the signs and symptoms of patients with psoriatic arthritis whose disease had not responded to prior therapies and independently, for those with ankylosing spondylitis,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences. “These findings represent an important step forward in our efforts to improve outcomes for people livin
First Data Polska Deploys Inside Secure’s Mobile Payment Technology To Securely and Easily Connect to Mastercard and Visa22.10.2018 15:36 | Pressemelding
Regulatory News: Inside Secure (Paris:INSD) (Euronext Paris: INSD), at the heart of security solutions for mobile and connected devices, today announced that First Data Polska S.A., a division of the global leader in commerce-enabling technology, selected Inside Secure technology to enable secure and flexible connections to Mastercard and Visa. First Data Polska S.A. chose Inside Secure’s Mobile Payment Client to easily integrate their solution with the Visa Token Service (VTS) and Mastercard Digital Enablement Service (MDES) – today’s major tokenization services that convert sensitive data into unique tokens that allow mobile payments to be processed. “Security and reliability are continual requirements for our services,” said Jolanta Rycerz, Member of Management Board at First Data Polska S.A. “We see Inside Secure as a valuable technology provider that enables us to easily migrate to the latest mobile payment technology and security standards. Thanks to Inside Secure, our customers,
PMI Launches Search for Next President and CEO22.10.2018 14:00 | Pressemelding
Project Management Institute (PMI), the world’s leading professional membership organization for project managers, announced today that it has retained Heidrick & Struggles to help the organization find its next President and Chief Executive Officer (CEO). The dynamic leader shall oversee the implementation of a new strategic plan and guide the organization toward a future designed to help thousands of project professionals around the world accelerate their careers and make ideas a reality. Heidrick & Struggles is a premier provider of executive search, leadership assessment and development, organization and team effectiveness, and culture shaping services globally. PMI will conduct a comprehensive global review of both internal and external candidates for this key position. The selected candidate will embody PMI’s core values and possess the skillsets necessary to advance the organization’s key goals. PMI’s next President and CEO will help it execute a bold new multi-year initiative d
E2open to Acquire INTTRA, Adding the World’s Leading Ocean Shipping Network and Software Provider, Creating an Integrated Global Supply Chain and Logistics Operating Network22.10.2018 13:43 | Pressemelding
E2open, the one place in the cloud to run your supply chain, today announced the acquisition of INTTRA, the leading ocean shipping network, software and information provider. The combination of INTTRA’s ocean carrier and shipper network with E2open’s industry leading business network will create a unified global logistics and supply chain network. E2open and INTTRA will join efforts to strengthen the connections and streamline the information flow between manufacturers, suppliers, shipping service providers, ocean carriers and all the participants in global trade. E2open is the largest cloud-based provider of networked supply chain solutions, featuring a complete portfolio of applications that enable the world’s most complex supply chains to better plan, collaborate, and execute their end-to-end operations. More than 70,000 partner companies and 200,000 users, many of the biggest brands and manufacturers across a range of industries, use the E2open network and platform to orchestrate t
Patient-Data Platform Raremark Raises £3m to Enable Precision Medicine in Rare Disease22.10.2018 12:00 | Pressemelding
Raremark, the leading patient-data platform in rare disease, has raised £3m in funding from investors, led by AlbionVC and Ananda Ventures, with participation from Oltre Venture and from existing major investor the Cass Entrepreneurship Fund. The funding will be used to develop Raremark’s patient-engagement and data-analysis technology, helping biopharmaceutical companies to identify, engage and learn from patients, accelerating the development of new treatments. Raremark’s platform is the foundation for building research networks of rare disease patients and their families. Raremark provides biopharmaceutical companies with access to anonymized and aggregated patient data, helping to reduce the time and cost of clinical development. The Raremark platform engages and retains patients, leveraging machine-learning technologies in novel ways. The approach is designed to raise health literacy and informed participation in medical research, to improve the quality of existing therapies and t